Ain Shams Movement Disorders Group (ASMDG)
ASMDG was founded in 2008 as the first specialized clinic for Parkinson’s disease and Movement Disorders in Egypt.
The vision of the unit is to establish an international center that provides comprehensive and specialized health care for patients with Parkinson’s disease and other movement disorders such as dystonia, tremor, chorea; provides advanced training and education in this filed; and conduct distinguishable scientific research in this field.
Vision & Mission
•Conducting long-term projects and drug-trials for movement disorders.
•Establishing center of excellence for movement disorders
•Providing advanced therapies for movement disorders.
•Hosting international activities and training African neurologists.
•International collaboration in scientific research funded by international scientific organization.
Education
•Provide annual training of Egyptians and non-Egyptian physicians.
•Organize national and international educational activities, including the 1st MDS Africa Movement Disorders School for Neurologists, Cairo 2019; Translational Neuroscience Summer School 2016, and 2017.
•Organizing international online educational activities including the MDS Africa multicenter bimonthly webinar 2020, and online movement disorders course 2017.
Clinical Services
Providing health care to patients of Parkinson’s disease and Movement Disorders, through two clinics/ week and in-patient services.
Establishing the functional neurosurgery for Movement disorders in collaboration with Ain Shams Neurosurgery department including ablative lesioning and advanced deep brain stimulation. Our group is considered pioneer and most experienced group in this field in Egypt.
The unit provides monthly medications for patients with Movement disorders as well.
Community Services
Fellowships and Observerships
National and International Collaboration
Collaboration with international societies (International Parkinson & Movement Disorders Society, IBRO), and Egyptian society of Neurology, Neurosurgery, & Psychiatry (ESNPN).
Publications
1. Shalash A, Okubadejo NU, Doumbe J, et al. Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries [published online ahead of print, 2020 Jun 18]. J Parkinsons Dis. 2020;10.3233/JPD-202040. doi:10.3233/JPD-202040
2. Shalash A, Roushdy T, Essam M, et al. Mental health, physical activity and quality of life in Parkinson’s disease during COVID-19 pandemic [published online ahead of print, 2020 May 19]. Mov Disord. 2020;10.1002/mds.28134. doi:10.1002/mds.28134
3. Shalash A, Hamid E, Elrassas H, Abushouk AI, Salem HH. Sexual dysfunction in male patients with Parkinson’s disease: related factors and impact on quality of life [published online ahead of print, 2020 Mar 14]. Neurol Sci. 2020;10.1007/s10072-020-04328-2. doi:10.1007/s10072-020-04328-2
4. Shalash AS, Mohamed H, Mansour AH, et al. Clinical Profile of Non-Motor Symptoms in Patients with Essential Tremor: Impact on Quality of Life and Age-Related Differences. Tremor Other Hyperkinet Mov (N Y). 2019;9:10.7916/tohm.v0.736. Published 2019 Dec 6. doi:10.7916/tohm.v0.736
5. Ali S Shalash, Abdelrahman Ibrahim Abushouk, Mohammed Yasser Elsherbeny, Hanan Elrassas, Taha Kamel. Refractory open jaw oromandibular tardive dystonia with a sensory trick, treated with botulinum toxin: A case report. Neurology India 2019; 67 : 4 : 1110—1111.
6. Rösler TW, Salama M, Shalash AS, Khedr EM, El-Tantawy A, Fawi G, El-Motayam A, El-Seidy E, El-Sherif M, El-Gamal M, Moharram M, El-Kattan M, Abdel-Naby M, Ashour S, Müller U, Dempfle A, Kuhlenbäumer G, Höglinger GU. K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson’s disease in Egypt. Sci Rep. 2018 Nov 8;8(1):16525. doi: 10.1038/s41598-018-35003-4.
7. Shalash AS, Hamid E, Elrassas HH, Bedair AS, Abushouk AI, Khamis M, Hashim M, Ahmed NS, Ashour S and Elbalkimy M (2018) Non-Motor Symptoms as Predictors of Quality of Life in Egyptian Patients with Parkinson’s Disease: A Cross-Sectional Study Using a Culturally Adapted 39-Item Parkinson’s Disease Questionnaire. Front. Neurol. 9:357. doi: 10.3389/fneur.2018.00357
8. Mohamed Salama, Ali Shalash, Alshimaa Magdy, Marianne Makar, Tamer Roushdy, Mahmoud Elbalkimy, Hanan Elrassas, Passent Elkafrawy, Wael Mohamed, Mohamed B Abou Donia. Cytoskeletal proteins, Tubulin and Tau, as targets for diagnosis of Parkinson’s and Alzheimer’s diseases. PLOS One, 2018; 13(5): e0196436.
9. Ben-Pazi H, Browne P, Chan P, Cubo E, Guttman M, Hassan A, Hatcher-Martin J, Mari Z, Moukheiber E, Okubadejo NU, Shalash A; International Parkinson and Movement Disorder Society Telemedicine Task Force. The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. Curr Neurol Neurosci Rep. 2018 Apr 13;18(5):26. doi: 10.1007/s11910-018-0834-6.
10. Shalash Ali, Abushady Eman, Hamid Eman, Salama Mohamed, Ibrahim Yosra. Patient with hemiparkinsonism secondary to a gun pellet in the contralateral substantia nigra. Movement Disorders clinical practice, Nov 2017.
11. Shalash Ali, Mohamed Salama, Marianne Makar, Tamer Roushdy, Hanan Elrassas, Wael Mohamed, Mohamed B Abou Donia, Mahmoud El-Balkimy. Elevated Serum alpha-synuclein autoantibodies in patients with Parkinson’s disease relative to Alzheimer’s disease and controls. Front. Neurol. 2017 Dec 22; 8: 720.
12. Shalash Ali, MD, Thomas W. Rösler, PhD, Stefanie H. Müller, M.Sc., Mohamed Salama, MD, Günther Deuschl, MD, Ulrich Müller, MD, Thomas Opladen, , Britt Sabrina Petersen, PhD, Andre Franke, PhD, MD, Franziska Hopfner, MD, Gregor Kuhlenbäumer, MD, PhD, Günter U. Höglinger, MD. c.207C.G mutation in sepiapterin reductase causes autosomal dominant dopa-responsive dystonia. Neurol Genet. 2017 Nov 1;3(6): e197.; doi: 10.1212/ NXG.0000000000000197.
13. Christian Schlenstedt, Ali Shalash, Muthuraman Muthuraman, Daniela Falk, Karsten Witt, Günther Deuschl. Effect of high frequency subthalamic neurostimulation on gait and freezing of gait in Parkinson’s disease: a systematic review and meta-analysis. European journal of neurology 2017 Jan;24(1):18-26.
14. Samia Ashour, Ahmed Gaber, Osama Aboelfotoh Aly, Saeed Hashem, Mohamed M Salama, Ali S Shalash. A Study of Extrapyramidal Manifestations Accompanying Decompensated Viral Hepatic Cirrhosis Patients. Reviews on Recent Clinical Trials. 2017 June;12:1-6.
15. Awad K, Abushouk AI, AbdelKarim AH, Mohammed M, Negida A, Shalash AS. Bee venom for the treatment of Parkinson’s disease: How far is it possible? Biomed Pharmacother. 2017 May 3;91:295-302.
16. Shalash AS, Hassan DM, Elrassas HH, Salama MM, Méndez-Hernández E, Salas-Pacheco JM, Arias-Carrión O. Auditory- and Vestibular-Evoked Potentials Correlate with Motor and Non-Motor Features of Parkinson’s Disease. Front Neurol. 2017 Feb 27;8:55.
17. Shalash, AS, Elrassas, HH, Monzem, MM, Salem, HS, Abdel Moneim, AN, and Moustafa RR. Restless Legs Syndrome in Egyptian medical students using a validated Arabic version of Restless Legs Syndrome Rating Scale. Sleep Medicine 16 (2015) 1528–1531.
18. Alexoudi A, Shalash AS, Knudsen K, Witt K, Mehdorn M, Volkmann J, Deuschl G. The medical treatment of patients with Parkinson’s disease receiving subthalamic neurostimulation. Parkinsonism Relat Disord. 2015; 2015 Jun;21(6):555-60.
19. Shalash AS, Elsayed SM, Elnaghi S, Schneider SA, Abdel Ghaffar TY. Prominent extensor truncal dystonia in Egyptian patients with Wilson’s disease. Movement disorders: official journal of the Movement Disorder Society 2014;29(1):151-153 (New observation).
20. Shalash A, Alexoudi A, Knudsen K, et al. The impact of age and disease duration on the long term outcome of neurostimulation of the subthalamic nucleus. Parkinsonism & related disorders 2014;20(1):47-52
